Achieving national cholesterol education program goals for low-density lipoprotein cholesterol in cardiac patients: Importance of diet, exercise, weight control, and drug therapy

Mayo Clinic Proceedings

Volumn 74, Issue 5, 1999, Pages 466-473

  Allison, Thomas G ^a   Squires, Ray W ^a   Johnson, Bruce D ^a   Gau, Gerald T ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONSTIPATION; CORONARY RISK; DIET THERAPY; EDUCATION PROGRAM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MYALGIA; WEIGHT REDUCTION;

EID: 0032891011     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/74.5.466     Document Type: Article

References (16)

1. National Cholesterol Education Program: second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1329-1445
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al (Cholesterol and Recurrent Events Trial Investigators). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng! J Med 1996; 335:1001-1009
4. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162
5. Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
6. DeBusk RF, Miller NH, Superko HR, Dennis CA, Thomas RJ, Lew HT, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994;120:721-729
7. Friedewald WT, Levy Rl, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
8. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-475
9. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-1388
10. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476-482
11. SAS Institute Inc. SAS Language and Procedures: Usage Version 6.12. Cary (NC): SAS Institute; 1998
12. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S (HERS Research Group). Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: Heart and Estrogen/Progestin Replacement Study (HERS). JAMA 1997;277:1281-1286
13. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, et al (LIPID Trial Research Group). Effects of lowering average of belowaverage cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy [published erratum appears in Circulation 1998;97:2479]. Circulation 1998:97:1784-1790
14. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-1131
15. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996:275:55-60
16. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, et al (Lifestyle Heart Trial). Can lifestyle changes reverse coronary heart disease? Lancet 1990:336:129-133